Binding of various antibody isotypes to B cells through either FcgRs or complement receptors has been attributed to play several roles, e.g. in immune complex (IC) transportation and regulation of B cell receptor signaling. We have revealed a novel B cell intrinsic receptor for IgM and IgG which is present in C57BL/6 (B6) mice and is more abundant in non-obese diabetic (NOD) mice. As a consequence, the level of extramembranous IgG monomers and IgM pentamers on peripheral blood B cells from NOD mice was significantly higher compared with B6 mice. The effect of this aberration was that all B cells in peripheral blood of (NOD.IgH a 3 B6(IgH b ))F 1 mice carried both IgM allotypes on their surface. In addition, analysis of IC binding using IgG-or IgM-opsonized bacterial particles revealed a higher degree of binding in NOD mice compared with B6. We hypothesize that this novel Igbinding receptor is part of the normal immune system function. The aberrant function in the NOD mouse could contribute to the development of Type 1 diabetes by altering normal B cell functions such as activation, IC transportation and B cell homeostasis.
Introduction
B cells are the main mediators of the humoral immune defense. In addition to expressing surface Igs and presenting antigens to T cells, B cells secrete antibodies that are distributed peripherally and involved in the neutralization and opsonization of foreign antigens. Furthermore, antigen-Ig immune complexes (ICs) can be transported to lymph nodes after which activation of various immune responses occurs. Interestingly, follicular B cells as well as marginal zone B cells can themselves act as antigen-transport cells, accomplishing this task through surface expression of complement receptors (1) . Moreover, B cells are involved in the phagocytosis of ICs through an Fc(al)R-dependent mechanism (2), which potentially could contribute to antigen presentation, although this has not yet been formally proven. Thus, the capability of B cells in this context is truly multifaceted.
During B cell development, allelic exclusion ensures that a particular B cell clone expresses one B cell receptor (BCR) specificity. However, a small subset (0.1%) of B cells express dual BCRs (3) . The consequence of this deviation for the particular B cell clone during a normal immune response has not been thoroughly established. It has also been demonstrated that a discrete subset of B cells in normal mice carry Igs that do not originate from the clone itself (4) . These Igs could be involved in the IC binding mentioned above or possibly act as non-clonally derived BCR-like molecules on the B cells, a feature that would alter our perception of how a normal immune response is initiated.
Although undoubtedly important in the adaptive immune system against pathogens, B cells are also key players in several autoimmune diseases, including Type 1 diabetes (5). This disease has been extensively studied in the autoimmune non-obese diabetic (NOD) mouse strain, which spontaneously develops diabetes due to selective destruction of pancreatic b cells in the islets of Langerhans (6) . Depletion of B cells in this model prevents NOD mice from developing Type 1 diabetes (7) (8) (9) , and NOD mice display enhanced and prolonged immune responses (10, 11) as well as an aberrant V H gene utilization pattern (12) . Moreover, B cells in NOD mice are indispensable as disease-promoting antigen-presenting cells (APCs) in their interaction with T cells (13) (14) (15) , which in turn also are critical for the development of Type 1 diabetes (16) (17) (18) .
Although B cells are essential in the development of Type 1 diabetes in the NOD mouse, a detailed and complete picture of the underlying mechanisms is still to be established. In this study, we describe that NOD B cells carry extramembranous IgM and IgG on their surface, a trait that we hypothesize has an impact on the development of diabetes.
Materials and methods

Mice
All mice used in this study were bred and maintained in the general animal facility at Umeå University. Experimental procedures were preformed in compliance with the relevant Swedish and Institutional laws and guidelines and approved by the Umeå research animal ethic committee. NOD (IgH b ), C57BL/6 (B6) (IgH b ) and BALB/c (IgH a ) mice were originally obtained from Bomholtgaard (Denmark). In our colony of female NOD mice, spontaneous diabetes occurs at an incidence of ;80% at 25 weeks of age. Age-matched females were used at 8-12 weeks of age. NOD.IgH a mice were established by crossing a NOD female with a BALB/c male and the litters were subsequently backcrossed to NOD >10 generations. In each generation, the mice were screened for the presence of IgM a -expressing cells in blood. After 10 backcrosses, the mice were intercrossed and one breeding pair was tested for residual BALB/c genome using a mouse low-density linkage panel, 377 SNPs (Illumina, San Diego, CA, USA). All positions tested were of the NOD allelic variant (data not shown). (NOD.IgH a 3 B6)F 1 mice and (BALB/c 3 B6)F 1 mice were bred and used at 8-12 weeks of age.
Cell isolation and enrichment
Blood was collected in PBS containing 2% heparin, and erythrocytes were hypotonically lysed by adding Gey's solution (7. . Splenic single-cell suspensions were prepared by pressing spleens between glass slides. B cells were enriched by MACS technique. Briefly, cells from blood or spleen were washed in PBS containing 0.5% BSA + 2 mM EDTA, incubated with CD19-labeled microbeads and collected using MACS MS separation columns (Miltenyi Biotech, Bergisch Gladbach, Germany), according to the manufacturer's recommendation. This purification step captures all B cell subsets except plasma cells, which do not express CD19. The purity was determined by flow cytometry and was consistently >95% (data not shown).
Flow cytometry
Isolated cells were re-suspended in PBS containing 3% FCS + 0.01% sodium azide (FACS buffer) and stained in round-bottom 96-well plates. In a first step (for some experiments as indicated), unlabeled anti-CD16/32 antibodies (clone: 2.4G2) were added for 20 min to block the Fc receptors (FcRs) CD16 and CD32. Thereafter, cells were washed and stained with labeled antibodies for 20 min on ice. Typically, 1 3 10 6 À 2 3 10 6 cells were stained using the following antibodies: anti-IgM a -PE (clone: DS-1), anti- In all flow cytometry analyses, lymphoid cells were distinguished from myeloid cells using FSC and SSC parameters in addition to surface marker expression.
Serum-and antibody-binding experiments
Spleen cells from B6 and NOD mice were incubated with FccR block as described above, and thereafter incubated with serum from either NOD.IgH a or BALB/c mice (i.e. NOD or B6 IgM b cells were incubated with NOD.IgH a or BALB/c IgM a serum). Cells were incubated for 20-60 min on ice, stained as indicated and analyzed by flow cytometry. In the binding experiments using the monoclonal PE-labeled isotype control antibodies (either mouse IgG or mouse IgM) (Caltag, Carlsbad, CA, USA), spleen and lymph node cells were first incubated with or without FccR block as indicated and then incubated with either antibody for 20 min on ice before being subjected to staining and flow cytometry analysis as described above. The level of bound IgM and IgG was determined as the median fluorescent intensity of all CD19
+ cells in the PE channel. To test the role of complement proteins in binding of PE-labeled IgM and IgG, antibodies and cells were kept in plain PBS instead of FACS buffer throughout the procedure as described above.
Western blot analysis
Isolated B cells from blood of NOD and B6 mice were lysed in a buffer containing 100 mM HEPES (pH 7.4), 150 mM NaCl, 10% Triton X-100 and a protease inhibitor cocktail tablet (Roche, Basel, Switzerland) on ice for 10-30 min. Lysate corresponding to the indicated amount of B cells was mixed with non-reducing sample buffer containing 60 mM Tris (pH 6.8), 20% glycerol and 2% SDS and electrophoresed on a 4% SDS-polyacrylamide gel (19) . Proteins were transferred onto a polyvinylidene fluoride membrane, blocked with 5% milk in PBS (pH 7.4) and incubated with l chainspecific goat anti-mouse IgM antibodies (Southern Biotech, Birmingham, AL, USA) overnight at 4°C. After washes with 0.5% Tween 20 in PBS, the membrane was incubated with HRP-conjugated rabbit anti-goat antibodies (Dako cytomation, Glostrup, Denmark) for 1 h at room temperature. Bands of IgM pentamers and monomers were detected using a chemiluminescent HRP substrate kit (Genscript, Piscataway, NJ, USA) according to the manufacturer's description and then quantified in a densitometer (Bio-Rad, GS-710 calibrated imaging densitometer). The relative pixel density was calculated as follows: number of pixels in the indicated sample/ number of pixels detected for B6.
IC trapping
Alexa488-labeled Staphylococcus aureus particles (Invitrogen) were brought into single-particle suspension according to the manufacturer's recommendation. Thereafter, the particles were incubated with either anti-S. aureus IgM, anti-S. aureus IgG (both from QED Biosciences, San Diego, CA, USA) or PBS for 1 h at 37°C. The opsonised particles were incubated overnight (18 h) with purified B cells (10 3 10 6 B cells ml À1 ) in complete medium: RPMI-1640 + Glutamax (Gibco, Carlsbad, CA, USA) supplemented with 10% FCS, 1 M HEPES buffer, 2 mM of L-glutamine, 100 U ml À1 penicillin, 100 lg ml À1 streptomycin and 55 lM b-mercaptoethanol. Cells were pre-treated with unlabeled anti-CD16/32 antibodies to block the FcR CD16 and CD32. Typically, a ratio of 1:2 (cell:bacteria) was used. After the overnight incubation, B cells were stained with PeCy7-labeled anti-CD19 antibodies as described above and analyzed by flow cytometry.
Confocal microscopy analysis
After overnight culture with either anti-S. aureus IgM, anti-S. aureus IgG or PBS, as described above, B cells were washed two times in PBS. Thereafter, cells were fixed for 10 min in cold 2% PFA at room temperature. After a subsequent wash with PBS, the cells were incubated with tetramethylrhodamine-conjugated wheat germ agglutinin (Molecular probes, Invitrogen) for 20 min at room temperature. Thereafter, cells were washed and cytospun onto slides. Images were acquired using a Leica SP2 laser scanning confocal microscope (the green and the red channels were scanned sequentially and stacks of images were obtained with a step size of 0.40 lm). Pictures were processed using Adobe Photoshop CS3 extended software (Adobe Systems, San Jose, CA, USA).
Cell proliferation analysis
Spleen cells from NOD and B6 mice were treated with Gey's solution to remove red blood cells, labeled in 1 lM carboxyfluorescein succinimidyl ester (10 min, 37°C) (Sigma-Aldrich, USA) and plated in 96-well plates (500 000 cells per well). Cells were stimulated with different combinations and concentrations of anti-l antibodies (SigmaAldrich) (for induction of proliferation), anti-trinitrophenol (TNP) (IgM a ) (clone: G155-228, BD Biosciences) (for binding to the potential receptor) and anti-IgM a (clone: RS3.1) (for cross-linking of bound anti-TNP antibodies) in complete RPMI. Proliferation of CD19-expressing cells at days 3, 4, 5 and 7 was assayed by flow cytometry analysis as described above.
Statistical analysis
Phenotypic differences between NOD and control strains were compared using Student's t-test. Significance levels were set to *P < 0.05 and **P < 0.005 as indicated. (Fig. 1A) . This feature 
Results
The observed occurrence of 'dual' surface-associated IgMs in (NOD.IgH a 3 B6 (IgH b ))F 1 mice leads us to suspect a defect in allelic exclusion. To resolve this issue, we performed intracellular staining for the two IgM allotypes after blockage of the IgM surface receptors. As shown in Fig. 1(B ))F 1 mice was not due to defective allelic exclusion but rather dependent on a non-intracellular component in NOD mice.
Ig-binding capability depends on the B cell origin
In NOD mice, it has been shown that the antibody repertoire is multi-reactive (12, 20) . This characteristic could potentially be the reason for the dual surface-associated IgMs. We therefore investigated whether the observed trait was dependent on a B cell intrinsic characteristic and/or resulted from components in the serum. Spleen cells from NOD or B6 mice were incubated in serum from BALB/c or NOD.IgH a mice, and the proportion of bound IgM a antibodies to B cells was determined. As shown in Fig. 2 , NOD B cells displayed higher IgM a binding compared with B6 B cells (P < 0.005), irrespective of the serum source, i.e. BALB/c or NOD.IgH a . In fact, B cells generally bound more IgM a antibodies when incubated with BALB/c serum compared with NOD.IgH a serum. Based on these results, we conclude that the observed trait dependent on a B cell intrinsic property and did not rely on the potential multi-reactivity of the antibodies or BCRs in the NOD mouse.
We also examined the Ig-binding property of B cells using PE-labeled monoclonal isotype control antibodies. After blocking FccRs, spleen and lymph node cells were + cells as described in Methods. The results are representative of three independent experiments; *P < 0.05, **P < 0.005. incubated with either IgM or IgG antibodies. As shown in Fig. 3(A and B) , NOD splenic B cells bound significantly more IgM and IgG antibodies (P < 0.005). In addition, we observed that NOD lymph node B cells bound significantly more IgM antibodies (P < 0.05). Other lymphoid organs tested, including bone marrow and peritoneal cavity, as well as T cells in general, did not exhibit this difference (data not shown). Importantly, the observed difference in IgM and IgG binding was not dependent on FccRs. Thus, incubation of splenocytes or lymph node cells with IgM and IgG antibodies, without prior FccR blockage, resulted in the reverse situation with a 4-fold higher binding to B6 B cells compared with NOD (Fig. 3C) (P < 0.005) . This observation is in line with several reports concerning defective FccR expression in NOD (21, 22) , and thus strengthens the notion that our observed phenotype is due to a still unidentified receptor.
Increased IgM pentamers and IgG antibodies on NOD peripheral blood B cells
To further assess the observed phenotype of NOD B cells in vivo, we sought to determine the relative amounts of IgM pentamers on the NOD B cell surface compared with B6 B cells. Purified peripheral CD19
+ blood B cells were subjected to western blot analysis using an IgM-specific antibody. An increase of surface-bound IgM pentamers was observed on NOD B cells (Fig. 4A) , and densitometer quantification revealed a 3-fold increase of bound IgM pentamers in NOD compared with B6 (Fig. 4B) . Interestingly, we also observed a 50% reduction in the expression of the BCR (IgM monomer) on NOD B cells, compared with B6 B cells.
We next analyzed the existence of extramembranous in vivo-bound IgG antibodies on IgM + B cells from peripheral blood of NOD and B6 mice. We observed a 2.5-fold increase in IgG b 1 surface level on IgM + B cells in NOD (P < 0.005) (Fig. 4C) . As binding of both IgM and IgG to NOD B cells was increased, we examined whether both isotypes bound to the same receptor. In sequential binding assays, we found that exposing B cells to saturating amounts of IgM antibodies, prior to binding with IgG, totally blocked the binding of the latter (data not shown). We therefore conclude that both IgM and IgG bound the same receptor and that binding was more efficient in NOD.
Enhanced capture of ICs by NOD B cells
Since it has been demonstrated that B cells can act as antigen-transport cells by binding ICs (23), we wanted to examine whether NOD B cells exhibited increased capability of IC capture. Purified splenic B cells were incubated with ICs consisting of IgG-or IgM-opsonized Alexa488-labeled S. aureus particles. After overnight culture, cells were stained Enhanced Ig binding to NOD B cells 537 with antibodies against CD19 and analyzed by flow cytometry (Fig. 5A) . Reproducibly, NOD B cells bound ;50% more ICs compared with B cells from B6 mice (Fig. 5B) , irrespective of opsonizing Ig isotype.
To examine if the captured ICs were endocytosed, purified splenic B cells with bound ICs were fixed and stained with tetramethylrhodamine-conjugated wheat germ agglutinin to be able to distinguish the plasma membrane. Using confocal scanning laser microscopy, we concluded that the captured ICs were solely located on the exterior part of the plasma membrane (Fig. 6A-D) . Cells incubated with non-opsonized S. aureus particles had bound one to two particles (Fig. 6A) . However, when the bacteria particles were opsonized with anti-S. aureus IgM or anti-S. aureus IgG, two distinct binding patterns were observed (Fig. 6B-C) . The majority of B cells had captured two to three large ICs, alternatively, capping of single captured particles had occurred. In addition, we noticed that some B cells had a dispersed binding of several particles (Fig. 6D) .
Discussion
We observed that peripheral blood B cells of (NOD.IgH a 3 B6(IgH b ))F 1 mice displayed dual surface-associated IgMs, which lead us to investigate the potential role of this aberration. In this paper, we demonstrate that the binding of IgM and IgG antibodies is not solely a NOD-specific trait since both B6 and NOD B cells display this property, although to different degrees. This suggests that the phenotype is part of the general immune system function.
Regulation of B cell activation, function and homeostasis is multifaceted. The involvement of free Igs and ICs together with FccRs as well as complement receptors has been extensively studied in this context. For example, the engagement of complement receptor CD21 has been implicated in the regulation of B cell activation (24, 25) and binding of FccRII-B1 inhibits B cell activation (26) . It was recently demonstrated that B cells could act as IC transporters within lymph nodes by a CD21/35-dependent mechanism (23) . Previous studies have also linked the expression of complement receptors, in particular on marginal zone B cells, to the capture, transportation and deposition of ICs in the spleen (1). The NOD mouse has an increased population of splenic marginal zone B cells (CD21 high ) (27) . However, we exclude the idea that the increased binding in NOD is due to the enlarged marginal zone subset since we observed that NOD B cells from organs other than the spleen, e.g. lymph nodes and peripheral blood, displayed increased levels of IgM and IgG binding. In these organs, marginal zone B cells are virtually absent. In addition, we have excluded the possibility of CD21/35-mediated binding of Igs via C3 derivates since we performed an IC trapping experiment in C3-deficient serum as well as tested the binding of PElabeled IgM and IgG in plain PBS and scored no difference compared with normal serum (data not shown).
The NOD mouse, as other autoimmune strains, displays defective expression of the FccIIb receptor (21) . This notion, together with the fact that we observed no effect on the capacity of NOD B cells to bind IgG irrespective of prior FccR blockage (in contrast to B6, where the binding increased without FccR blockage), indicates that FccRs are not responsible for the binding. We also examined the FcalR which is expressed on B cells and traps ICs, in particular of the IgM type (2) . We analyzed the published FcalR sequence for NOD and B6, as well as examined the transcriptional level of FcalR in an Illumina microarray assay for NOD and B6 B cells. Neither of these analyses (data not shown) revealed any difference between the two strains, hence excluding the FcalR as a prime receptor/ligand candidate. It has recently been described that B cells upon activation reciprocally exchange parts of their cell membranes, including BCRs (28), particularly if activated in vitro. We tested whether NOD B cells, upon LPS activation, were more potent to acquire portions of neighboring cells' membranes and BCRs, compared with B6 and BALB/c. We observed no difference between the strains analyzed (data not shown). In addition, as we observed the dual Ig occurrence particularly on B cells in blood (that are rapidly and separately moving), we rule out this mechanism as a possible explanation for our described phenomenon. CD19 is also a suggested Enhanced Ig binding to NOD B cells 539 receptor for IgM (29) . In addition, CD19 influences the threshold for B cell activation (30) . In line with this, we have observed that the level of CD19 was consistently 1.2-1.5 times higher on NOD B cells (measured as MFI in flow cytometry analysis) compared with B6 (data not shown). These data, however, did not correlate with the degree of IgM binding for the different organs, and IgG has previously been excluded as a CD19 ligand (30) . Based on this, we exclude CD19 as the candidate receptor.
In NOD mice, it has been shown that the antibody repertoire is multi-reactive (12, 20) . It is plausible that this feature could contribute to binding of Igs. However, we consider this possibility less likely since (i) we did not observe higher levels of Ig binding in young mice from other strains which also show the feature of multi-reactivity (31), (ii) we observed that the older the (NOD.IgH a 3 B6(IgH b ))F 1 mice are, the more apparent was the dual expression pattern, while selection against multi-reactivity are more evident the older the mice become (31) and (iii) we found that serum antibodies from NOD actually bound to the cells to a lower extent compared with serum antibodies from BALB/c mice. On the basis of this, we conclude that the receptor for our observed IgM and IgG binding is still to be revealed.
It is worth noticing that all our binding experiments, except for the IC-binding experiments, were performed on ice and in most cases only for 20 min. To establish binding in such a short time under low-temperature conditions requires a relatively high-affinity/avidity receptor-ligand interaction. Although we have not done any affinity measurements, future identification of the receptor will allow this.
IC binding could potentially influence B cell proliferation. We could, however, not detect any effect on B cell proliferation in a series of in vitro experiments (data not shown). Alternatively, the enhanced Ig binding to B cells in the NOD mouse could have consequences for the immune response. Appearance of affinity-matured pentamers on B cells has previously been shown in a NP-BSA immunization system (4). In this study, the authors argued that the trait could enhance a normal immune response. Interestingly, the NOD mouse has previously been shown to display an enhanced and prolonged immune response (10, 11) . In addition, B cells are essential for driving the autoimmune response in the NOD mouse, i.e. B cell-deficient NOD mice do not develop diabetes (8, 9) . B cells are also important APCs in this process (13) (14) (15) . Since we observed a higher degree of IC binding to NOD B cells, it is plausible that this occurs in vivo for natural antigens (i.e. capture and transportation of ICs) and thus could promote a too strong, uncontrollable immune response.
Allelic exclusion is a cornerstone of adaptive immunity. Our observation that B cells from NOD mice display extramembranously associated IgMs and IgGs has not changed this fact. However, it has widened our perspective of the functional consequences of such binding and pinpointed yet another fascinating aspect of regulation and dysregulation of immune responses.
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